Literature DB >> 20713179

A 30-year, population-based study shows improved management and prognosis of hepatocellular carcinoma.

Boris Guiu1, Anne Minello, Vanessa Cottet, Côme Lepage, Patrick Hillon, Jean Faivre, Anne-Marie Bouvier.   

Abstract

BACKGROUND & AIMS: Little is known about the impact of changes in the management of hepatocellular carcinoma (HCC) over time. We assessed trends in the pattern of care and in prognosis at a population level.
METHODS: Data on diagnostic conditions, treatment, and prognosis from 1976-2005 were collected by the population-based digestive cancer registry of Burgundy (France). A nonconditional logistic regression was used to identify factors associated with treatment for cure. A multivariate relative survival analysis was also performed.
RESULTS: The context of HCC diagnosis has changed; the proportion of asymptomatic patients increased from 5.6% (1976-1985) to 37.2% (1996-2005). The proportion of cases diagnosed on the basis of morphologic criteria increased from 14% during 1976-1985 to 35.6% during 1996-2005, whereas histologically verified cases decreased from 62.2% to 41.2% between the same time periods. The proportion of patients who were treated with intent to cure increased from 2.7% (1976-1985) to 19.6% (1996-2005). This increase was associated with improvements in relative survival from 4.7% (1976-1985) to 32.8% (1996-2005) at 1 year and from 1.4% to 10.0% at 5 years. The 5-year relative survival of patients treated with curative intent increased, reaching 46.6% for the 1996-2005 period. In the multivariate relative survival analysis, age, period of diagnosis, clinical presentation, alpha-fetoprotein level, and treatment were independent prognostic factors.
CONCLUSIONS: During a 30-year period, there was an increase in the number of HCCs diagnosed in asymptomatic subjects that was associated with the development of new effective therapies; this association might account for improvements in prognosis of patients with HCC.
Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20713179     DOI: 10.1016/j.cgh.2010.07.018

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  5 in total

1.  Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008.

Authors:  Ju Dong Yang; Bohyun Kim; Schuyler O Sanderson; Jennifer L St Sauver; Barbara P Yawn; Rachel A Pedersen; Joseph J Larson; Terry M Therneau; Lewis R Roberts; W Ray Kim
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

2.  Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.

Authors:  Atsushi Nanashima; Naota Taura; Takafumi Abo; Tatsuki Ichikawa; Ichiro Sakamoto; Takeshi Nagayasu; Kazuhiko Nakao
Journal:  Dig Dis Sci       Date:  2011-06-25       Impact factor: 3.199

3.  Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging: A potential utility for the evaluation of regional liver function impairment following transcatheter arterial chemoembolization.

Authors:  Yu-Dong Xiao; Ramchandra Paudel; Huan Liu; Bin Zhang; Cong Ma; Shun-Ke Zhou
Journal:  Oncol Lett       Date:  2014-12-23       Impact factor: 2.967

4.  Different Features of 18F-FAPI, 18F-FDG PET/CT and MRI in the Evaluation of Extrahepatic Metastases and Local Recurrent Hepatocellular Carcinoma (HCC): A Case Report and Review of the Literature.

Authors:  Donghe Chen; Chengdong Chang; Yafei Zhang; Shuye Yang; Guolin Wang; Lili Lin; Xin Zhao; Kui Zhao; Xinhui Su
Journal:  Cancer Manag Res       Date:  2022-09-05       Impact factor: 3.602

5.  Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan.

Authors:  Yih-Jyh Lin; Chia-Ni Lin; Tannaz Sedghi; Sylvia H Hsu; Cary P Gross; Jung-Der Wang; Shi-Yi Wang
Journal:  PLoS One       Date:  2020-10-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.